20 February 2018 Effect of linkers on the αvβ3 integrin targeting efficiency of cyclic RGD-conjugates
Author Affiliations +
Abstract
Cyclic arginine-glycine-aspartic acid (cRGD) peptides are well known to target ανβ3 integrin expressed on cancer cells and neovasculature. Conjugation of these peptides with dyes, drugs, antibodies and other biomolecules through covalent linkers provides a facile way to deliver these products to tumor cells for targeted cancer therapy and diagnosis. Click chemistry and acid-amine couplings are widely used conjugation strategies. However, the effects of different linkers and the distance between the cRGD and the conjugates on the binding of cRGD ligand with ανβ3 has been underexplored.

In this present study, we prepared cRGD-conjugates using different linkers and determined how they altered the tumor targeting efficiency in vitro and in vivo. The results demonstrate that different linkers significantly altered the pharmacokinetics of the cRGD conjugates and the tumor uptake kinetics. Unlike large antibodies, this preliminary finding shows that linkers used to attach drugs and fluorescent molecular probes to small peptides play a major role in the accuracy of tumor targeting and treatment outcomes. As a result, considerable attention should be paid to the nature of linkers used in the design of molecular probes and targeted therapeutics.
© (2018) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Partha Karmakar, Partha Karmakar, Dorota Grabowska, Dorota Grabowska, Gail Sudlow, Gail Sudlow, Kostiantyn Ziabrev, Kostiantyn Ziabrev, Nibedita Sanyal, Nibedita Sanyal, Samuel Achilefu, Samuel Achilefu, } "Effect of linkers on the αvβ3 integrin targeting efficiency of cyclic RGD-conjugates", Proc. SPIE 10508, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications X, 1050809 (20 February 2018); doi: 10.1117/12.2301223; https://doi.org/10.1117/12.2301223
PROCEEDINGS
11 PAGES


SHARE
Back to Top